Science
Heart Failure
Explore
Heart Failure (HF) is a clinical syndrome characterized by the impairment of the heart to circulate blood to different parts of the body. The prevalence of HF is about 1-3% of the general adult population, estimated to affect more than 64 million people worldwide. HF is a leading cause of hospitalization and cardiovascular death.
Selective SGLT2 inhibitors have demonstrated benefits in heart failure patients with reduced ejection fraction and preserved ejection fraction (HFrEF and HFpEF), decreasing the risk of cardiovascular-related hospitalization and death. The proposed mechanisms are many-fold, and new insights contributing to our understanding increases every day.
YG1699, a systemic dual SGLT1 and SGLT2 inhibitor, has potential to further improve upon the benefits observed with selective SGLT2 inhibitors. By attaining systemic SGLT1 inhibition in the kidney, small intestines, as well as the heart, potential for a greater risk reduction in cardiovascular-related hospitalization or death is very promising. In addition, evidence suggests inhibiting SGLT1 with SGLT2 can reduce the risk of myocardial infarction and stroke compared to selective SGLT2 inhibitors. FDA has approved in August 2022 that YG1699 can directly conduct clinical phase II trials in the U.S.
